TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Changes from baseline CD133+/KDR+ at 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Changes from baseline CD34+/KDR+ at 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Functional transcranial doppler measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants Who Required Transfusion
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of the immunogenic personal neoantigen vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Time to 50% reduction in abnormal serum free light chain concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to 50% reduction in M-protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete molecular remission persistence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major VTE
Endpoint domain: Adverse events/effects
Primary endpoint: Changes of the hippocampal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sensitivities of FISH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with accurate diagnosis of eye diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ovarian follicular density
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Eradication of CRKP carriage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Microcirculation assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Maximal oxygen uptake (VO2max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Nausea Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in the Parent-Young Mania Rating Scale (P-YMRS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in blood pressure from baseline to endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in medication adherence from baseline to endpoint
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Arteriole to venule ratio (AVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Toronto Western Spasmodic Torticollis Scale (TWSTRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Experiencing Hypoglycemic Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants Experiencing Mild, Moderate, Severe, or Very Severe Hypoglycemic Episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Hemoglobin A1c <7.0%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Functional status/activities of daily living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: feasibility of hypothermia induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brachial artery reactivity (flow-mediated vasodilation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall Image Quality Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesion Based Standard Uptake Values (SUV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Receiver Operating Characteristic Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants completing study exercises
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence of gastrointestinal (GI) bleedings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of Helicobacter Pylori Infection Cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Regrowth of eyebrows and eyelashes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of hospital stay (days)
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of Intensive Care Unit admissions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Operative Times
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Positive DTH skin test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Feasibility of EBV-specific adoptive T cell therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of EBV-specific adoptive T cell therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Time to Stand Test (TTSTAND) Velocity in Rises/Second Change From Baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HSCL 25
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Signs or symptoms of phentermine dependence
Endpoint domain: Adverse events/effects
Primary endpoint: B cell phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: B cell ELISPOT assay results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Convenience Satisfaction Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Accuracy of the Custom Made Miniplate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean perceived social support for physical activity
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: anterior resection syndrome incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Induction-to-abortion interval time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention in and adherence to HIV care
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: impact of life events
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Incidence of respiratory viruses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Geometric Mean Anti-typhoid Vi Antibody Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Anti-Yellow Fever Antibody Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Anti-Japanese Encephalitis Neutralizing Antibody Titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean Anti-Rabies Virus Neutralizing Antibody Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Combined score of residual AHI and Epworth score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AAA diameter evolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: External version success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Reintubation rates
Endpoint domain: Adverse events/effects
Primary endpoint: wrist motion range
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ulnar sided pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean inspiratory airway pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in Scale for the Assessment and Rating Ataxia (SARA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical cure at the end of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with no additional antibiotic therapy required
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic steatosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of tumor responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: HIV DNA load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of undetectable minimal residual disease (MRD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of unacceptable toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Functional Ambulation Profile (SCI-FAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Oral Mucositis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sound production accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety measured by percentage of Treatment Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability measured by percentage of Treatment Emergent Adverse Events (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of nerve catheter displacement
Endpoint domain: Adverse events/effects
Primary endpoint: Number of wards that agree to hosting the HIIT Pilot Study
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of people who consent to take part
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Average adherence to HIIT sessions and assessments
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Cardiovascular Risk Knowledge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Nutrition Knowledge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Resolution of chronic cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geographic Atrophy (GA) Lesion Growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maturation rate of AVF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary and secondary patency rate of AVF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Cognitive Dysfunction Biomarker (Mismatch Negativity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Cognitive Dysfunction Biomarker (Visual Event-Related Potential [ERP])
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Cognitive Dysfunction Biomarker (N1 Refractoriness)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Cognitive Dysfunction Biomarker (P3 Component)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Cognitive Dysfunction Biomarker (Visual Evoked Potential [VEP])
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: changes of microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Post-ischemic Forearm Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intensity of pain during injections
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic and prognostic value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: neurologic events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: secondary organ injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with dose-limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Protein kinetics and balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-year Disease Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Significant circulating tumor cells (CTCs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Evolution of Cobb angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appearances of complications
Endpoint domain: Adverse events/effects
Primary endpoint: Late persistence of complications
Endpoint domain: Adverse events/effects
Primary endpoint: 'Aversive amplification circuit' connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tryptophan metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Patients Progression Free at 6 Months
Endpoint domain: Mortality/survival
Primary endpoint: Percentage With Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: end-tidal sevoflurane concentration to blockade adrenergic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of new malignancies
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of adverse events of special interest (AESI)
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of Asparaginase Activity >100 U/L
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Allergic Reaction During Induction Phase
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of systemic inflammatory response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Composite score of clinical and biochemical signs of disease activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Apnea Hypopnea Index (AHI) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of major depressive episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depressive symptom trajectories
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mean serum Mg2+ treatment effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Event-Free Survival (EFS) in Participants with Diffuse Large B-Cell Lymphoma
Endpoint domain: Mortality/survival
Primary endpoint: Event-Free Survival (EFS) in Participants with Hodgkin's Lymphoma
Endpoint domain: Mortality/survival
Primary endpoint: Event-Free Survival (EFS) in Participants with T-Cell Lymphoma
Endpoint domain: Mortality/survival
Primary endpoint: Area under the time-concentration curve (AUC) for serum concentrations of peginterferon beta-1a
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of sensorial block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in H-reflex amplitude from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change in Cutaneomuscular Reflex Responses from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Total attendance to antenatal care clinic
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence proportion of persistent flares
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Nasal mucosal secretions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HCV RNA Viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Serum Concentration-time Curve From Time Zero to Infinity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-vitro production of hydrogen and methane in feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Recovery of ingested bacteria in feces by PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 6 months late lumen loss in the target lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Total amount of calorie provision during hospitalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Body weight change for 2 months after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma AUCinf of dextromethorphan and dextrorphan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma AUClast of dextromethorphan and dextrorphan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Cmax of dextromethorphan and dextrorphan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects who achieve seroconversion and seroprotection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequencies of AEs including vaccine-related reactogenicity events
Endpoint domain: Adverse events/effects
Primary endpoint: BMI variation from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: insulin doses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of experienced hypoglycaemic events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of patients agreeing to switch ARV regimen
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Area Under the Concentration-time Curve (AUC 0-8 and AUC 0-inf) of ZTI-01
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Measured Plasma Concentration (Cmax) of ZTI-01
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood flow pattern changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance gained beyond depth of maximal insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in HAM-D Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Functional Connectivity using BOLD rsfMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of sleep apnea events per hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Change in Minutes of Moderate Physical Activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Consumptions of clotting factors/desmopressine
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total clinical breast pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Referrals to Supportive Care Services
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: End of Conversion to Open Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Bispectral index score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abuse liability potential
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Sputum Culture acid-fast bacilli microscopy Conversion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Anxiety Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Depressive Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Resilience Level
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Medication Administered in Error
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration (AUC 0-t) of Tepotinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC 0-inf) of Tepotinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 18F-FES uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Postoperative Synechiae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Behaviour regulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Subjective health measure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recommended dose of PT-112
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful resection of bladder tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Blood pressure in range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood pressure over range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood pressure below range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in the OHQ Composite Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status